CTMX
CytomX Therapeutics, Inc. NASDAQ Listed Oct 8, 2015$2.95
-0.34%
vs $2.96
Mkt Cap $406.9M
52w Low $1.76
23.8% of range
52w High $6.75
50d MA $3.82
200d MA $4.06
P/E (TTM)
-19.7x
EV/EBITDA
—
P/B
4.1x
Debt/Equity
0.0x
ROE
-17.5%
P/FCF
-5.4x
RSI (14)
22.20
ATR (14)
$0.17
Beta
2.48
50d MA
$3.82
200d MA
$4.06
Avg Volume
3.9M
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
151 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.14 | -0.10 | +28.6% | 4.00 | +1.0% | -0.5% | -3.0% | +0.5% | -2.3% | -0.3% | — |
| Mar 16, 2026 | AMC | -0.08 | -0.22 | -175.0% | 6.75 | +2.5% | -19.3% | -19.3% | +8.6% | -6.9% | +0.2% | — |
| Nov 6, 2025 | AMC | -0.05 | -0.09 | -82.5% | 4.19 | -9.3% | -13.6% | +15.7% | -2.1% | +3.2% | -8.7% | — |
| Aug 7, 2025 | AMC | -0.06 | -0.00 | +98.0% | 2.10 | -2.4% | +11.9% | -1.7% | -19.5% | -4.3% | -1.1% | — |
| May 12, 2025 | AMC | 0.12 | 0.27 | +116.3% | 2.13 | +1.9% | +17.4% | -4.8% | -16.0% | +1.5% | +4.9% | — |
| Mar 6, 2025 | AMC | -0.23 | 0.22 | +195.7% | 0.62 | +15.0% | +7.7% | +0.7% | -7.4% | -3.5% | -1.3% | — |
| Nov 7, 2024 | AMC | -0.17 | 0.07 | +141.2% | 1.00 | +15.0% | +9.0% | -4.6% | +0.0% | -2.9% | -1.0% | — |
| Aug 8, 2024 | AMC | -0.14 | -0.08 | +42.9% | 1.18 | +0.8% | +1.7% | -0.8% | -2.5% | +0.0% | +2.6% | — |
| May 8, 2024 | AMC | -0.08 | 0.17 | +312.5% | 4.19 | -35.1% | -51.3% | -2.9% | -4.5% | +2.6% | +1.0% | — |
| Mar 11, 2024 | AMC | 0.00 | 0.01 | +133.8% | 2.51 | -19.5% | -14.3% | -2.3% | -1.9% | +0.5% | -2.4% | — |
| Nov 7, 2023 | AMC | -0.19 | 0.04 | +121.1% | 1.28 | +0.8% | -2.3% | -4.0% | -2.5% | +5.1% | +4.1% | — |
| Aug 8, 2023 | AMC | -0.20 | -0.02 | +90.0% | 1.69 | +0.0% | -3.6% | +4.9% | -1.8% | -2.4% | -3.0% | — |
| May 9, 2023 | AMC | -0.11 | -0.05 | +54.9% | 1.72 | +3.5% | +5.8% | -2.7% | +0.6% | +2.2% | -3.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Wolfe Research | Initiates | Outperform | $6 | $3.50 | $3.54 | +1.1% | +4.0% | +2.2% | +1.1% | +0.0% | -1.9% |
| Mar 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.45 | $4.48 | +0.7% | +0.2% | -4.9% | -0.5% | +4.7% | +2.3% |
| Mar 19 | Barclays | Maintains | Overweight → Overweight | — | $4.40 | $4.51 | +2.5% | +8.6% | -6.9% | +0.2% | -4.9% | -0.5% |
| Mar 18 | Jefferies | Maintains | Buy → Buy | — | $5.45 | $5.27 | -3.3% | -19.3% | +8.6% | -6.9% | +0.2% | -4.9% |
| Mar 18 | Guggenheim | Maintains | Buy → Buy | — | $5.45 | $5.27 | -3.3% | -19.3% | +8.6% | -6.9% | +0.2% | -4.9% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $6.75 | $6.92 | +2.5% | -19.3% | -19.3% | +8.6% | -6.9% | +0.2% |
| Mar 16 | JP Morgan | Upgrade | Neutral → Overweight | — | $4.68 | $6.92 | +47.9% | +44.2% | -19.3% | -19.3% | +8.6% | -6.9% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.68 | $6.92 | +47.9% | +44.2% | -19.3% | -19.3% | +8.6% | -6.9% |
| Mar 9 | Guggenheim | Maintains | Buy → Buy | — | $4.68 | $4.61 | -1.5% | +7.5% | -3.0% | +0.0% | -0.2% | -3.9% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $6.07 | $6.19 | +2.0% | -6.6% | -7.6% | +8.2% | +0.5% | -3.0% |
| Feb 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.07 | $6.19 | +2.0% | -6.6% | -7.6% | +8.2% | +0.5% | -3.0% |
| Jan 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.39 | $5.46 | +1.3% | -0.4% | -1.5% | +8.1% | -3.1% | -3.6% |
| Jan 20 | Barclays | Maintains | Overweight → Overweight | — | $5.39 | $5.46 | +1.3% | -0.4% | -1.5% | +8.1% | -3.1% | -3.6% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.19 | $4.19 | +0.0% | -2.1% | +3.2% | -8.7% | +0.5% | -8.5% |
| Oct 21 | Barclays | Maintains | Overweight → Overweight | — | $3.74 | $3.90 | +4.3% | -3.2% | -6.4% | -2.7% | -1.2% | +3.1% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.13 | $2.14 | +0.5% | -3.3% | -1.0% | +4.4% | +4.7% | -4.5% |
| May 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.38 | $2.50 | +5.0% | -16.0% | +1.5% | +4.9% | -3.3% | -1.0% |
| May 15 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.38 | $2.50 | +5.0% | -16.0% | +1.5% | +4.9% | -3.3% | -1.0% |
| Apr 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $0.53 | $0.55 | +3.3% | +13.8% | +4.2% | -0.3% | +4.2% | +14.3% |
| Mar 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.62 | $0.71 | +15.0% | +7.7% | +0.7% | -7.4% | -3.5% | -1.3% |
| Jan 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.14 | $1.15 | +0.9% | -10.5% | -3.6% | -10.4% | +0.8% | -5.2% |
| May 28 | Piper Sandler | Upgrade | Neutral → Overweight | — | $1.75 | $1.92 | +9.7% | +2.3% | -2.2% | +0.0% | -2.9% | +2.9% |
| May 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $4.19 | $2.72 | -35.1% | -51.3% | -2.9% | -4.5% | +2.6% | +1.0% |
| May 9 | Wedbush | Upgrade | Neutral → Outperform | — | $4.19 | $2.72 | -35.1% | -51.3% | -2.9% | -4.5% | +2.6% | +1.0% |
| May 6 | Jefferies | Upgrade | Hold → Buy | — | $4.43 | $4.89 | +10.4% | -1.4% | -6.9% | +2.9% | -51.3% | -2.9% |
| May 1 | BMO Capital | Maintains | Market Perform → Market Perform | — | $1.63 | $3.25 | +99.4% | +214.7% | -12.3% | -1.6% | -1.4% | -6.9% |
| Apr 22 | JP Morgan | Upgrade | Underweight → Neutral | — | $1.67 | $1.76 | +5.4% | +0.0% | +0.6% | -3.0% | -1.8% | -0.6% |
| Mar 12 | BMO Capital | Maintains | Market Perform → Market Perform | — | $2.51 | $2.02 | -19.5% | -14.3% | -2.3% | -1.9% | +0.5% | -2.4% |
| Mar 12 | Wedbush | Maintains | Neutral → Neutral | — | $2.51 | $2.02 | -19.5% | -14.3% | -2.3% | -1.9% | +0.5% | -2.4% |
| Nov 9 | Wedbush | Maintains | Neutral → Neutral | — | $1.25 | $1.25 | +0.0% | -4.0% | -2.5% | +5.1% | +4.1% | +0.8% |
| Nov 8 | Wedbush | Upgrade | Neutral → Outperform | — | $1.28 | $1.29 | +0.8% | -2.3% | -4.0% | -2.5% | +5.1% | +4.1% |
| Aug 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $1.69 | $1.69 | +0.0% | -3.6% | +4.9% | -1.8% | -2.4% | -3.0% |
| Mar 28 | Mizuho | Maintains | Neutral → Neutral | — | $1.79 | $1.48 | -17.3% | -15.1% | +1.0% | -3.6% | +2.0% | +2.0% |
| Jan 6 | BMO Capital | Maintains | Market Perform → Market Perform | — | $1.79 | $2.96 | +65.4% | +40.8% | +14.3% | -3.5% | -1.4% | -0.4% |
| Nov 14 | BMO Capital | Downgrade | Outperform → Market Perform | — | $1.29 | $1.25 | -3.1% | -1.6% | -6.3% | +1.7% | +32.2% | +8.8% |
| Nov 10 | JP Morgan | Downgrade | Overweight → Underweight | — | $1.24 | $1.19 | -4.0% | +1.6% | +2.4% | -1.6% | -6.3% | +1.7% |
| Jul 11 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.30 | $1.28 | -1.5% | -1.5% | +0.0% | +1.6% | +7.7% | +7.1% |
| Jul 11 | TD Cowen | Downgrade | Outperform → Market Perform | — | $1.30 | $1.28 | -1.5% | -1.5% | +0.0% | +1.6% | +7.7% | +7.1% |
| Jul 7 | Mizuho | Downgrade | Buy → Neutral | — | $1.97 | $1.41 | -28.4% | -37.6% | +5.7% | -1.5% | +0.0% | +1.6% |
| Jul 7 | Piper Sandler | Downgrade | Overweight → Neutral | — | $1.97 | $1.41 | -28.4% | -37.6% | +5.7% | -1.5% | +0.0% | +1.6% |
| Jul 7 | BMO Capital | Maintains | Outperform → Outperform | — | $1.97 | $1.41 | -28.4% | -37.6% | +5.7% | -1.5% | +0.0% | +1.6% |
| Jul 7 | Barclays | Maintains | Overweight → Overweight | — | $1.97 | $1.41 | -28.4% | -37.6% | +5.7% | -1.5% | +0.0% | +1.6% |
| Jul 7 | Wedbush | Downgrade | Outperform → Neutral | — | $1.97 | $1.41 | -28.4% | -37.6% | +5.7% | -1.5% | +0.0% | +1.6% |
| Jul 7 | Jefferies | Downgrade | Buy → Hold | — | $1.97 | $1.41 | -28.4% | -37.6% | +5.7% | -1.5% | +0.0% | +1.6% |
| Jul 7 | BTIG | Maintains | Buy → Buy | — | $1.97 | $1.41 | -28.4% | -37.6% | +5.7% | -1.5% | +0.0% | +1.6% |
| Jun 24 | BMO Capital | Maintains | Outperform → Outperform | — | $1.87 | $1.95 | +4.3% | +1.6% | +2.1% | -4.1% | +0.5% | -2.1% |
| Mar 2 | JP Morgan | Maintains | Overweight → Overweight | — | $3.54 | $3.89 | +9.9% | +14.1% | -5.4% | -2.9% | +1.3% | +1.3% |
| Jan 18 | Barclays | Upgrade | Underweight → Overweight | — | $3.95 | $4.18 | +5.8% | -3.0% | +6.5% | +2.0% | +3.1% | +2.3% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.87 | $3.81 | -1.6% | +4.7% | +4.2% | +0.2% | +2.6% | +3.0% |
| Nov 15 | BTIG | Maintains | Buy → Buy | — | $7.02 | $7.16 | +2.0% | +3.4% | +1.8% | -0.3% | -2.0% | +1.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Ogden Christopher | Chief Financial Officer | Sell | 1,624 | $3.05 | $5K | 295,324 | -0.34% | — |
8-K
CytomX Therapeutics, Inc. -- 8-K Filing
Jun 3
8-K
Unknown — 8-K Filing
Cortimelix raised capital through an offering to fund Varseta-M development and operations, diluting existing shareholders but providing runway for clinical progress and investor returns.
Mar 19
8-K
Unknown — 8-K Filing
CytomX announced a corporate action on March 16, 2026, but the incomplete filing lacks material details, making it impossible to assess impact on the stock until full disclosure is available.
Mar 16
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 31,955,637 | $150M | Added | Mar 2026 |
| 2 | Vr Adviser, Llc | 15,561,500 | $66M | — | Dec 2025 |
| 3 | Bank Of America Corp /de/ | 10,202,785 | $48M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 8,733,118 | $41M | New | Mar 2026 |
| 5 | Point72 Asset Management | 7,875,390 | $37M | Added | Mar 2026 |
| 6 | Citadel Advisors Llc | 5,406,193 | $25M | Added | Mar 2026 |
| 7 | Marshall Wace, Llp | 4,138,176 | $19M | Added | Mar 2026 |
| 8 | Millennium Management | 3,660,190 | $17M | Added | Mar 2026 |
| 9 | Adar1 Capital Management, Llc | 3,410,190 | $16M | New | Mar 2026 |
| 10 | Ubs Group Ag | 3,120,155 | $15M | Added | Mar 2026 |
| 11 | Two Sigma Investments, Lp | 2,710,156 | $13M | Added | Mar 2026 |
| 12 | Qube Research & Technologies Ltd | 2,249,583 | $11M | Added | Mar 2026 |
| 13 | Woodline Partners Lp | 2,000,825 | $9M | Reduced | Mar 2026 |
| 14 | Susquehanna International Group, Llp | 1,869,615 | $9M | Added | Mar 2026 |
| 15 | Ally Bridge Group (Ny) Llc | 900,000 | $4M | New | Mar 2026 |
| 16 | Vanguard Portfolio Management Llc | 794,755 | $4M | New | Mar 2026 |
| 17 | Morgan Stanley | 802,382 | $3M | Added | Dec 2025 |
| 18 | Northern Trust Corp | 612,141 | $3M | Added | Mar 2026 |
| 19 | Bnp Paribas Financial Markets | 606,275 | $3M | Added | Mar 2026 |
| 20 | Ensign Peak Advisors, Inc | 592,473 | $3M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$406.9M
Enterprise Value
$269.9M
P/E (TTM)
-19.67x
Forward P/E
—
PEG Ratio
0.24x
P/B
4.11x
P/S
5.34x
P/FCF
-5.37x
EV/EBITDA
—
Shares Out
137.9M
Financials (TTM)
Revenue
$76.2M
Net Income
-$17.4M
EBITDA
-$18.2M
Free Cash Flow
-$75.8M
Op Cash Flow
-$75.6M
EPS Basic
$-0.15
EPS Diluted
$-0.15
EPS Forward
$-0.46
Gross Margin
100.0%
Op Margin
-25.7%
Net Margin
-22.8%
Balance Sheet
Total Assets
$151.6M
Total Liab.
$52.6M
Total Equity
$99.0M
Cash
$137.1M
LT Debt
$0
Book Value/Sh
$0.72
Debt/Equity
0.04x
Current Ratio
3.09
Quick Ratio
3.09
Returns & Growth
ROE
-17.5%
ROA
-11.5%
ROIC
-17.9%
Rev Growth YoY
-44.8%
EPS Growth YoY
-139.5%
Price Returns
2W
-4.8%
1M
-14.7%
3M
-33.0%
6M
-15.9%
12M
+35.8%
Technicals
52W High
$6.75
52W Low
$1.76
50d MA
$3.82
200d MA
$4.06
RSI (14)
22.20
ATR (14)
$0.17
Beta
2.48
Avg Volume
3.9M
Dividends
Div Rate
$0.02
Div Yield
0.5%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.60
High
$16.00
Low
$10.00
Median
$10.00
Data updated apr 25, 2026 3:43am
· Source: financialmodelingprep.com